-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Jim Greenwood
State of the Industry Address from 2010 BIO International Convention
This was the opening slide for my talk in Atlanta last year. We found ourselves then in the midst of a perfect storm of economic meltdown, political volatility and scientific challenge. We knew that these challenges would bring significant change to our industry but that if we remained confident, we would emerge from these challenges better and stronger. We have. Let me tell you why I say that. Biotech stocks have outperformed virtually every other Read More >
A Disin‘gene’uous Lawsuit: ACLU Challenges DNA Patents
From the mass production of life-saving medicines in cell cultures to the screening of our blood supply for life-threatening viruses, patented DNA molecules (often referred to as “gene patents”) are used in many ways to benefit society. The term “gene patent” is something of a misnomer because genes as they exist in the body cannot be patented. A naturally occurring gene — even a newly discovered one — cannot be patented. Patents don’t provide ownership Read More >
Countering Misinformation On Biosimilars
One of the impediments to a reasonable public dialogue regarding the creation of a pathway for the approval of biosimilars has been the deluge of misinformation. It is difficult to choose where to begin in correcting the numerous falsehoods in a recent guest editorial in the New York Times (“Biologics Boondoggle”; 3/8/10). To start, the authors claim that the provisions in the House and Senate health care reform bills would “discourage the development and significantly Read More >
Looking for Long-Term Economic Signs at BIO Partnering Meetings
In its 30-year history, biotechnology has made dramatic advances possible in health care, agriculture, energy production and industrial bioprocessing. These accomplishments are the result of painstaking work by many smart people devoted to transforming bench-scale life-science research into commercial products. In economic times both strong and weak this industry thrives. The industry and the promise of its science were tested during the recent and continuing recession. Many biotech companies were forced to downsize or even Read More >
Millions Around World to Observe Rare Disease Day
On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS). Plans for the day—and the days leading up to it—include awareness events sponsored by patient organizations, a rally organized by pre-medical students at the University of Connecticut, a scientific symposium at the Read More >




